The US Court of Appeals for the Federal Circuit has rejected Biogen’s bid to block a generic version of its multiple sclerosis drug, pending an appeal against a lower court’s ruling.
In a victory for the University of California, the European Patent Office has affirmed a CRISPR patent issued to Emmanuelle Charpentier, the University of California, and the University of Vienna.
A competitor of the Broad Institute has said that a European Patent Office ruling last week has weakened the CRISPR/Cas9 patent owner’s negotiating hand in any future settlement between the parties.
A US judge has thrown out a lawsuit accusing US biotechnology companies Illumina and Affymetrix of a “complex, multi-decade concerted effort” to conceal the theft of trade secrets in the 1990s.
In a dramatic reversal, a European Patent Office’s board of appeal has upheld the revocation of a Broad Institute CRISPR/Cas9 patent.
The European Patent Office intends to refer questions in the Broad Institute’s ongoing CRISPR patent case to the enlarged board of appeal, meaning the case is set to drag out further.
The first day of a landmark hearing on CRISPR ownership dealt nearly exclusively with untangling linguistic arguments, lawyers following the proceedings told LSIPR.
Gene-sequencing companies Illumina and Pacific Biosciences have “mutually agreed” to terminate their $1.2 million merger agreement, under which Illumina would have acquired PacBio.
The US Patent and Trademark Office has granted the University of California its 20th US patent on CRISPR-Cas9 gene-editing technologies.
Syngenta will be allowed to raise claims that Willowood infringed its copyright by copying warning labels on pesticides, the US Court of Appeals for the Federal Circuit ruled yesterday, December 18.